Aby J. Mathew Sells 425 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 425 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $25.46, for a total transaction of $10,820.50. Following the completion of the sale, the executive vice president now directly owns 262,198 shares in the company, valued at approximately $6,675,561.08. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

BioLife Solutions Trading Up 5.7 %

BLFS stock traded up $1.41 during midday trading on Wednesday, reaching $26.25. The stock had a trading volume of 502,346 shares, compared to its average volume of 270,046. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. The business has a fifty day simple moving average of $26.67 and a two-hundred day simple moving average of $25.48.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. As a group, research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BLFS shares. HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. Benchmark reiterated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp increased their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Finally, Craig Hallum increased their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently made changes to their positions in BLFS. Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions during the fourth quarter worth about $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions in the 3rd quarter valued at approximately $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions during the fourth quarter valued at approximately $31,000. Quest Partners LLC acquired a new position in BioLife Solutions during the third quarter valued at approximately $57,000. Finally, 1620 Investment Advisors Inc. increased its stake in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.